Blade Therapeutics' $353M SPAC Go-Public Deal Called Off
Blank-check company Biotech Acquisition Co. and biopharmaceutical group Blade Therapeutics Inc. said Monday they are canceling their previously announced nearly $353 million merger, marking the latest in a number of special-purpose...To view the full article, register now.
Already a subscriber? Click here to view full article